Patents by Inventor Kuan-Lang Lai

Kuan-Lang Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Muparfostat for use in treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection
    Patent number: 10842804
    Abstract: Muparfostat for use in reducing intrahepatic tumor recurrence and increasing disease-free survival period in a hepatocellular carcinoma patient with microvascular invasion after curative liver resection, while excluding HCC patients with no vascular invasion and HCC patients with macrovascular invasion, is disclosed. The hepatocellular carcinoma patient with microvascular invasion is identified by examining a resected liver tumor sample from the HCC patient for the presence of microvascular invasion in the sample.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 24, 2020
    Assignee: Medigen Biotechnology Corporation
    Inventors: Stanley Chang, Kuan-Lang Lai
  • MUPARFOSTAT FOR USE IN TREATING PATIENTS WITH HEPATITIS VIRUS-RELATED HEPATOCELLULAR CARCINOMA AFTER SURGICAL RESECTION
    Publication number: 20180250317
    Abstract: Muparfostat for use in reducing intrahepatic tumor recurrence and increasing disease-free survival period in a hepatocellular carcinoma patient with microvascular invasion after curative liver resection, while excluding HCC patients with no vascular invasion and HCC patients with macrovascular invasion, is disclosed. The hepatocellular carcinoma patient with microvascular invasion is identified by examining a resected liver tumor sample from the HCC patient for the presence of microvascular invasion in the sample.
    Type: Application
    Filed: February 8, 2018
    Publication date: September 6, 2018
    Inventors: Stanley Chang, Kuan-Lang Lai
  • PHARMACEUTICAL COMPOSITION FOR USE IN INHIBITING RECURRENCE, AGGRAVATION AND METASTASIS OF HEPATOCARCINOMA
    Publication number: 20180215775
    Abstract: The present application provides a pharmaceutical composition for use in inhibiting recurrence, aggravation or metastasis of liver cancer, in which the pharmaceutical composition comprises at least one compound having a structure of formula (I) and a pharmaceutically acceptable vehicle.
    Type: Application
    Filed: March 15, 2018
    Publication date: August 2, 2018
    Inventors: Stanley CHANG, Kuan-Lang Lai
  • PHARMACEUTICAL COMPOSITION FOR USE IN INHIBITING RECURRENCE, AGGRAVATION AND METASTASIS OF HEPATOCARCINOMA
    Publication number: 20140135282
    Abstract: The present application provides a pharmaceutical composition for use in inhibiting recurrence, aggravation or metastasis of liver cancer, in which the pharmaceutical composition comprises at least one compound having a structure of formula (I) and a pharmaceutically acceptable vehicle.
    Type: Application
    Filed: June 9, 2011
    Publication date: May 15, 2014
    Applicant: MEDIGEN BIOTECHNOLOGY CORP
    Inventors: Stanley Chang, Kuan-Lang Lai